Data Insights

Azercabtagene zapreleucel by Imugene for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Azercabtagene zapreleucel by Imugene for Non-Hodgkin Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Non-Hodgkin Lymphoma

Data Insights

Azercabtagene zapreleucel by Imugene for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Data Insights

Azercabtagene zapreleucel by Imugene for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...

Data Insights

Azercabtagene zapreleucel by Imugene for Mantle Cell Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...

Data Insights

Azercabtagene zapreleucel by Imugene for Follicular Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...

Data Insights

Azercabtagene zapreleucel by Imugene for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...

Data Insights

Azercabtagene zapreleucel by Imugene for Follicular Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Follicular Lymphoma

Data Insights

Azercabtagene zapreleucel by Imugene for Mantle Cell Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Mantle Cell Lymphoma

Data Insights

Azercabtagene zapreleucel by Imugene for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Azercabtagene Zapreleucel in Diffuse Large B-Cell Lymphoma